Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380399 | 1.00 | BCHE (0.46) | BCHEKDM1AP2RX4HDAC1HDAC6 | |
| Indole SCHEMBL27827279 | 0.87 | TRPA1 (0.38) | BCHEKDM1AP2RX4HDAC1HDAC6 | |
| Quinoline SCHEMBL28294326 | 0.86 | PDE10A (0.38) | BCHEKDM1AGRM5GRM1GPR119 | |
| SCHEMBL27739868 | 0.85 | BCHE (0.48) | BCHEKDM1AP2RX4HDAC1HDAC6 | |
| SCHEMBL7112196 | 0.84 | KDM1A (0.37) | BCHEKDM1AP2RX4HDAC1HDAC6 | |
| Oxindole SCHEMBL28307962 | 0.84 | AHR (0.44) | BCHEKDM1AHDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL27785934 | 0.83 | P2RX4 (0.58) | BCHEP2RX4LMNASMN1; SMN2MAPK1 | |
| SCHEMBL27957065 | 0.82 | AHR (0.41) | BCHEKDM1AHDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL28304244 | 0.82 | NR1H2 (0.35) | BCHEKDM1AHDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL29549990 | 0.81 | SMN1; SMN2 (0.53) | BCHEP2RX4LMNASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| CN-117881680-A | Tricyclic compounds as KRAS inhibitors | 因赛特公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110167935-B | 3-substituted propionic acids as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-112805006-A | PRMT5 inhibitor | 默沙东公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-112585138-A | 4-substituted pyrrolo [2,3-b ] pyridines as ErbB modulators useful in the treatment of cancer | 利德探索中心有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-110483482-A | Indoline -1- Carbox amide, preparation method and its in application pharmaceutically | BEIJING INNOCARE PHARMA TECH CO LTD | 2019-11-22 | — | — | CN | disclosed |
| CN-106029656-B | Oxindole derivatives, its preparation and its therapeutical uses in treatment AMPK related disease | 赛诺菲 | 2019-07-26 | — | — | CN | disclosed |
| CN-106029656-A | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases | 赛诺菲 | 2016-10-12 | — | — | CN | disclosed |
| US-8383584-B2 | HCV inhibiting macrocyclic phenylcarbamates | MEDIVIR AB (SE) | 2013-02-26 | — | — | US | disclosed |
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1532113-A2 | SUBSTITUTED HIHYDROQUINOLINES AS GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | disclosed |
| US-20040157880-A1 | Indoline and tetrahydro-quinolines as prodrugs for tumour treatment | UNIVERSITY OF BRADFORD (GB) | 2004-08-12 | — | — | US | disclosed |
| EP-1408970-A1 | INDOLINES AND TETRAHYDRO-QUINOLINES AS PRODRUGS FOR TUMOUR TREATMENT | THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2004-04-21 | — | — | EP | disclosed |
| WO-2004018429-A2 | SUBSTITUTED HIHYDROQUINOLINES AS GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2002067937-A1 | INDOLINE AND TETRAHYDRO-QUINOLINES AS PRODRUGS FOR TUMOUR TREATMENT | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2002-09-06 | — | — | WO | disclosed |
| EP-1114031-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017164-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157880-A1 | Indoline and tetrahydro-quinolines as prodrugs for tumour treatment | CYP1B1, TOP1, UGT1A1 | BCHE 2155/4885KDM1A 458/4885P2RX4 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.